Second HMA/EMA Multi-Stakeholder Forum on EudraVigilance and Signal Detection

Twenty-five years after EudraVigilance went live, the Heads of Medicines Agencies and EMA bring stakeholders back together to mark the anniversary and look at what comes next for EU signal detection — broadcast live and in Amsterdam, 1 December 2026.

Dates and format

• Date: 1 December 2026, all day (exact start/end time not yet published)
• Format: online with a live broadcast, and in person at EMA, Amsterdam
• Organizer: Heads of Medicines Agencies (HMA) and European Medicines Agency (EMA)
• Registration: process, deadline and any fee to be announced by the organizer

What it covers

EudraVigilance, the EU's central database for suspected adverse drug reaction reports, turns 25 in 2026. This second multi-stakeholder forum — following the first in November 2025 — brings regulators, industry and other stakeholders together to review ongoing and forthcoming developments in international pharmacovigilance guidance, signal management updates and the growing use of real-world evidence in signal detection, and to strengthen engagement across the stakeholder community. It sits alongside EMA's other autumn stakeholder sessions in a season heavy with EU pharmacovigilance and safety-monitoring updates.

Who should attend

Pharmacovigilance and drug safety leads tracking EudraVigilance's signal-management roadmap, plus regulatory affairs staff who need to anticipate how EU safety reporting and real-world evidence requirements are evolving. For the broader EU pharmacovigilance calendar, EMA's SME Info Day and the full events directory cover adjacent sessions we have verified.